Answers are grounded in this paper and cite their sources.
Randomized controlled trial showed solriamfetol improved fatigue and executive function in ME/CFS patients, indicating potential therapeutic benefits.
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a long-term illness with no treatment options that address the disease directly. Solriamfetol is a selective dual norepinephrine-dopamine reuptake inhibitor that promotes wakefulness in obstructive sleep apnea and narcolepsy. Aims: This study evaluated the efficacy and safety of solriamfetol for fatigue symptoms in adults with ME/CFS over 8 weeks of treatment. Methods: This was a phase 4, double-blind, randomized, placebo-controlled trial of solriamfetol in adults with ME/CFS. Eligible participants ( N = 38) were randomly assigned to receive 75 mg (titrated to 150 mg as needed) solriamfetol or placebo. Participants completed a battery of assessments at weekly visits. The primary outcome was Fatigue Symptom Inventory (FSI) scores, and the secondary outcome measure was Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A), at Weeks 6 and 8. T-tests assessed the differences in mean change from baseline between solriamfetol and placebo. Adverse events were monitored throughout the study. Results: At Week 8 ( p = 0.039), but not Week 6 ( p = 0.270), solriamfetol improved FSI severity compared to placebo. On the BRIEF-A global executive composite, solriamfetol improved more than placebo at Week 8 ( p = 0.012), driven by improved metacognition index ( p = 0.004), but not behavioral regulation index ( p = 0.574). Solriamfetol was well tolerated, with most common AEs being sleep loss and headaches. Conclusions: Solriamfetol demonstrated good safety and efficacy in improving fatigue and executive functioning in patients with ME/CFS. As a dual norepinephrine-dopamine reuptake inhibitor and wakefulness-promoting factors, solriamfetol has the potential to improve fatigue symptoms of ME/CFS. Clinical trial number: NCT04622293
No takes yet. Share an insight, caveat, or question.
Young et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: